Revolution Medicines CEO Sells Over $17.9M in Company Stock

Mark A. Goldsmith, the President and Chief Executive Officer of Revolution Medicines, Inc., reported significant trading activity in the company's stock. On August 21, 2026, Goldsmith executed a series of transactions under a pre-arranged 10b5-1 trading plan adopted on May 22, 2026.

The activity involved both an acquisition and multiple dispositions. Goldsmith exercised stock options to acquire 80,000 shares of Common Stock at a price of $4.73 per share. Concurrently, he sold a total of 85,990 shares of Common Stock in numerous trades at weighted average prices ranging from approximately $207.23 to $212.13.

The total value of the shares sold amounts to approximately $17.99 million. These sales were conducted both directly by Goldsmith and indirectly through various trusts. Following these transactions, Goldsmith's total beneficial ownership, including direct holdings and shares held in trusts, is 984,238 shares of Common Stock. The exercise of options followed by sales is a common practice for executives to realize value from equity compensation and cover associated tax liabilities. The high value of the sale makes this a significant liquidity event for the insider.